Acurx Pharmaceuticals, Inc.
ACXP
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum ( GPSS ) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid ( DNA ) polymerase II…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$8M
▲ +43.5% YoY
Op. Margin
–
ROIC
-94.10%
▲ +1596.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7M
▲ +34.6% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$10M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ACXP
Acurx Pharmaceuticals (ACXP) in two numbers
Questions about Acurx Pharmaceuticals
Does Acurx Pharmaceuticals (ACXP) pay a dividend?
No. Acurx Pharmaceuticals (ACXP) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ACXP's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ACXP
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.